July 2022 Br J Cardiol 2022;29:102–5 doi:10.5837/bjc.2022.024
Selwyn Brendon Goldthorpe
Introduction Dr Selwyn Brendon Goldthorpe Indications for the use of pacemakers and implantable cardioverter-defibrillators (ICDs) have become more defined over time, resulting in many more patients receiving these devices.1 Cardiac implantable electronic device (CIED) procedure is the term used to encompass pacemaker and ICD implant surgery. As of 2016, it was estimated that there were about 1.14 million pacemakers globally. By the year 2023, that number is expected to increase to 1.43 million units.2 Many nations are now keeping records of the implant complication rate for pacemakers and ICDs.3-6 As in any surgical procedure, a complication
June 2021 Br J Cardiol 2021;28:73–6 doi:10.5837/bjc.2021.027
Eliza Foster, Guy Furniss, Mark Dayer
Introduction There has been a steady increase in the number of cardiac implantable electronic devices (CIEDs) fitted in the UK over the last decade, and common complications of CIED insertion include bleeding or bruising at the insertion site, pneumothorax, lead displacement and infection. Complications of device insertion are common. Some of the largest datasets come from Denmark. In 2013, an analysis of 5,918 consecutive cases found that 2.4% of patients required a lead-related re-intervention, 0.9% developed a pneumothorax, 0.8% developed infection, 0.6% had a cardiac perforation and 0.2% developed a haematoma requiring re-operation.1 More
You need to be a member to print this page.
Find out more about our membership benefits
You need to be a member to download PDF's.
Find out more about our membership benefits